Pages

Monday, March 2, 2015

Jazz Pharmaceuticals Is Undervalued

Jazz product sales will beat Q1's high estimate on price increases alone, but there is much room to grow organically. Jazz Pharmaceuticals is a large biopharmaceutical company with a market cap of $10.63 billion.

http://ift.tt/1GcQGiR

No comments:

Post a Comment